Janssen - Cilag Spa. – FDA 483, Jan 21, 2019
An FDA inspection of Janssen Cilag via C. Janssen snc in Latina, Italy, revealed significant deficiencies in laboratory controls and data integrity. The firm failed to ensure the accuracy and reliability of test results, specifically regarding the integration and reporting of degradation peaks for tablet batches. Additionally, the Empower chromatographic system software was found to be inadequately configured, with unspecified integration parameters that could prevent the detection of critical components in pharmaceutical products.
ID · 5ae9e9fd-66eb-46e4-abec-fe3e29f48687
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.